余位不多，赶紧上车 - 第6届生物产品和公司估值研讨会邀请函 2017年6月2日，珠海
灵麦医药有限公司携手Venture Valuation诚邀您参加为期一天的生物医药产品与公司评估的研讨会
理解生物制药领域广泛运用的估值的概念和方法
了解如何评估和计算生物医药公司的价值
学习如何评估在研药品的价值以及如何去谈判产品的授权交易
日期: 2017年06月02日 周五 8:30 - 17:00
地点: 华发喜来登酒店, 中国珠海
费用:
会员公司: 14,000 RMB/人
非会员公司: 15,000 RMB/人
*以上价格不含税
注：4月30日前报名可享12,000RMB/人早鸟价
研讨会至多容纳20位参会者
通过课程，你能学习：
了解决定生命科学领域生物医药产品和制药公司估值的因素
全面掌握和认识关键评估条款，概念，工具和方法
学习并练习：
a) 如何在估值之前用模型去评估生物医药公司的非客观因素
b) 如何利用一款可以带回家的Excel工具计算在研化合物的价值并将其应用于其他任何一在研药物产品
c) 如何组织药企与生物技术企业之间的专利授权交易，包括如何确定阶段性的付款模式及专利费用从Patrik Frei那里获取专家视点和指导，Patrik Frei已经在生命科学领域评估了大量的产品和公司
与中国各大医药领域公司BD部门专家有近距离交流，分享心得与经验
培训师—Patrik Frei:
Patrik是欧洲顶尖的高速成长型生命科学公司的估值专家；Patrik是Venture Valuation AG公司的创始人和首席执行官，擅长在生物科技和生命科学领域中进行独立评价和新兴高成长型公司的估值；Patrik和他的团队曾一起帮助诺华投资基金实施了所有的外部估值；他也是全球生命科学数据库—博谷（Biotechgate）的开发者
日程安排
08:30
签到
09:00
会议开始并致辞
09:15
估值的具体介绍
课程的概述
估值的基础知识
估值的主要意图：衡量风险与回归
10:00
如何在估值之前评估一家公司
为何在进行估值之前先了解一家公司是非常重要的
三大重要环节：管理-技术-市场
评估一家公司的20个必要因素
10:30
休息
10:45
公司估值,互动环节：
简述对生命科学医药公司估值的途径（例：定价）和为何简单的方法却能更有效
重点讲解一些已经实践过的估值方式：
a) 现金流折扣
b) 企业资本方式
c) 市场/交易比较估值的实际操作 – 实例探讨
小组合作实践环节：
参会者将会被分组，在得到一个案例时，每一小组将有机会来评估一个生命科学公司。随后向其他小组展示并互相讨论其估值结果
12:30
午餐
13:45
产品估值与交易结构,互动环节：
公司与产品估值的不同
什么样的信息是你所需要的 – 如何去获取所需要的信息？
简述产品估值方式
深入阐述在制药与生物技术领域常用的方法：风险调整净现值（rNPV）
如何从各种产品的估值中评估这家公司
凭借风险调整净现值（rNPV）,如何决定最佳交易结构（预付款，里程碑期付款等？）
如何使用产品估值来决定一个合适的交易结构?
小组合作实践环节
参会者将会被分组，在得到一个案例时，每一小组将有机会来评估一个在开发阶段的 制药产品。
随后向其他小组展示并互相讨论其估值结果
在研讨活动中会有下午茶时间
16:15
研讨会总结
17:00
结束
咨询报名请联系 info@lingmed.net / 021-5386 3003，或点击“阅读原文”注册报名， 报名截止日为2017年5月20日。
LINGMED LIMITED SHANGHAI together with Venture Valuation is pleased to invite you to a full-day workshop on pharma-biotech Product and Company Valuation
Understand the valuation concepts and techniques that are commonly applied in the pharma and biotech world
Know how to assess and calculate the value of a biotech company
Learn how to calculate the value of a pharmaceutical in development and how to structure a licensing deal
Date:
June 2, 2017 Friday, 8:30-17:00
Location:
SHERATON ZHUHAI HOTEL, Zhuhai, China
FEE:
Subscriber: 14,000RMB/person
Non-subscriber:15,000RMB/person
*Price exclusive of tax
*12,000RMB/person for early bird registration before April 30, 2017
Maximum participants: 20
Course Benefits
Know what determines the value of life science biotechs and emerging pharma companies
Gain a thorough understanding of key valuation terms, concepts, tools&techniques
Learn and practice how to:
a) Use a model that assesses the soft factors of a biotech company prior to its valuation
b) Calculate the value of a development compound with an excel tool you can take home and use for any other pharmaceutical product in development
c) Structure licensing deals between pharma and biotech, covering issues such as milestones and royalty paymentsGain expert insight and advice from Patrik Frei who has assessed and valued numerous products and companies in the life science industry
-
Network and share experiences with BD professionals in China
The Trainer – Patrik Frei
Patrik is the Europe's top valuation expert of high-growth life science companies; Patrik is Founder & CEO of venture Valuation AG, specializing in independent assessments and valuation of emerging high-growth companies in biotechnology and the sciences; Patrik and his team carried out all external valuations for the Novartis Venture Fund; Owner of Biotechgate the global life science database
Course agenda
08:30
Registration & Welcome coffee
09:00
Welcome
09:15
Introduction to Valuation: what –why –when
Scope of this course
Basics about valuation
The main drives of valuation : measuring risk vs return
10:00
How to Assess a Company Prior to Valuation
Why is it important to assess a company before doing a valuation
The three key areas management-technology-market
The 20 factors required to assess a company
10:30
Coffee break
10:45
Company Valuation
Interactive lecture:
An overview of approaches for valuing life science companies (e.g. option pricing) and why simple approaches work best
Focus on the most used company valuation methods:
a) Discount Cash Flows
b) Venture Capital method
c) Market / Deal comparableValuation in practice - discussion of a historical case
Group work on a case study：
The audience will be broken up in groups. After reading the case, each group has the opportunity to calculate the value of a life science company. The groups will then present and discuss their results in a plenary discussion
12:30
Lunch
13:45
Product Valuation & Deal Structuring
Interactive lecture:
Difference between company and product valuation
What information do you need? - How to gather the information?
Overview of product valuation methods
In-depth explanation of the most frequently used technique in Pharma & Biotech:the Risk-adjusted Net Present Value(rNPV)
How to calculate the value of a company from several product valuations
Given an rNPV, how to decide on the best deal structure (upfront payment, milestone payments, royalties and etc?)
How to use the product valuation to determine a suitable deal structure?
Group work on a case study
The audience will be broken up in groups.After reading the case, each group has the opportunity to calculate the value of a pharmaceutical product in development. The groups will then present and discuss their results in a plenary discussion
Coffee will be served during the case study workshop
16:15
Final Discussion & Wrap-up
17:00
Closing
For any further enquiries, please contact info@lingmed.net /+86 21 5386 3003, or click "read more" below to state your name and company by May 20, 2017.
